Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted ...
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus recommendation of “Moderate ...
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback